Comparative Pharmacology
Head-to-head clinical analysis: CARTIA XT versus ISRADIPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARTIA XT versus ISRADIPINE.
CARTIA XT vs ISRADIPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cells during depolarization, leading to vasodilation and reduced myocardial contractility and conduction velocity, particularly at the AV node.
Isradipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into vascular smooth muscle and myocardial cells via L-type calcium channels, leading to vasodilation and reduced peripheral vascular resistance, with minimal negative inotropic effect.
Diltiazem hydrochloride extended-release capsules (CARTIA XT) are administered orally. For hypertension and angina, the typical adult dose is 180–360 mg once daily, initially 180 mg once daily, titrated to response.
2.5-10 mg orally twice daily. Initial dose: 2.5 mg twice daily, titrate to 5-10 mg twice daily as needed.
None Documented
None Documented
Clinical Note
moderateIsradipine + Etacrynic acid
"The risk or severity of adverse effects can be increased when Isradipine is combined with Etacrynic acid."
Clinical Note
moderateIsradipine + Furosemide
"The risk or severity of adverse effects can be increased when Isradipine is combined with Furosemide."
Clinical Note
moderateIsradipine + Bumetanide
"The risk or severity of adverse effects can be increased when Isradipine is combined with Bumetanide."
Clinical Note
moderateIsradipine + Travoprost
Terminal half-life 3-4.5 hours; prolonged in hepatic impairment (up to 15 hours) or with cimetidine.
Terminal elimination half-life 8 hours (range 6-12 hours); clinical context: supports twice-daily dosing, requires dose adjustment in hepatic impairment.
Renal (biliary/fecal minimal). 70-80% excreted as inactive metabolites in urine; 15% unchanged.
Renal: 65% (as metabolites, <1% unchanged); Fecal: 35% (biliary elimination); total clearance 1.4 L/min.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker
"Isradipine may increase the hypotensive activities of Travoprost."